Squarepoint Ops LLC lowered its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 49.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 98,473 shares of the company’s stock after selling 97,508 shares during the quarter. Squarepoint Ops LLC’s holdings in Teva Pharmaceutical Industries were worth $677,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of TEVA. Advisor Group Inc. increased its holdings in Teva Pharmaceutical Industries by 4.3% in the 2nd quarter. Advisor Group Inc. now owns 51,375 shares of the company’s stock worth $473,000 after buying an additional 2,101 shares during the period. Janus Henderson Group PLC increased its holdings in Teva Pharmaceutical Industries by 434.2% in the 2nd quarter. Janus Henderson Group PLC now owns 1,353,935 shares of the company’s stock worth $12,496,000 after buying an additional 1,100,481 shares during the period. Wedbush Securities Inc. increased its holdings in Teva Pharmaceutical Industries by 12.5% in the 2nd quarter. Wedbush Securities Inc. now owns 31,944 shares of the company’s stock worth $295,000 after buying an additional 3,559 shares during the period. TD Asset Management Inc. increased its holdings in Teva Pharmaceutical Industries by 8.3% in the 2nd quarter. TD Asset Management Inc. now owns 315,980 shares of the company’s stock worth $2,916,000 after buying an additional 24,100 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its holdings in Teva Pharmaceutical Industries by 72.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 185,882 shares of the company’s stock worth $1,688,000 after buying an additional 77,895 shares during the period. Hedge funds and other institutional investors own 53.39% of the company’s stock.
Shares of NYSE:TEVA traded down $0.24 during midday trading on Monday, reaching $9.72. 13,645,600 shares of the company’s stock traded hands, compared to its average volume of 16,882,309. Teva Pharmaceutical Industries Ltd has a 1 year low of $6.07 and a 1 year high of $20.21. The company has a market cap of $10.88 billion, a P/E ratio of 3.47, a PEG ratio of 1.07 and a beta of 1.82. The company has a debt-to-equity ratio of 1.62, a quick ratio of 0.56 and a current ratio of 0.89. The company has a fifty day simple moving average of $10.01 and a two-hundred day simple moving average of $8.33.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, November 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. The business had revenue of $4.26 billion for the quarter, compared to analysts’ expectations of $4.25 billion. As a group, research analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.26 EPS for the current fiscal year.
Several equities research analysts have commented on TEVA shares. Wells Fargo & Co lowered their price objective on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating on the stock in a research report on Monday, September 30th. Gabelli upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, October 16th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $8.00 price objective on the stock in a research report on Tuesday, November 12th. ValuEngine lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 3rd. Finally, Guggenheim started coverage on Teva Pharmaceutical Industries in a research report on Thursday, September 12th. They issued a “neutral” rating on the stock. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Teva Pharmaceutical Industries has an average rating of “Hold” and an average price target of $10.64.
In other news, VP Hafrun Fridriksdottir sold 4,310 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.49, for a total transaction of $45,211.90. Following the transaction, the vice president now owns 24,883 shares in the company, valued at approximately $261,022.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.49% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: What sectors are represented in the FTSE 100 index?
Receive News & Ratings for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.